Understanding the impact of genetic variability in drug response is an important component of the implementation of personalised medicine. However, rapid and widespread introduction of robust and acceptable genetic tests is yet to happen. This symposium will review the reasons for this and the current state of play with regard to the translation of research findings into clinical practice.